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of expected medical and economic outcomes in popula-
tion subgroups. METHODS: A published, editable dia-
betes model was used to assess the outcomes of different
degrees of secondary prevention measures for different
diabetes type 2 patient sub-groups in Germany. Clinical
data were derived from German diabetes quality of care
circles. Incremental cost-effectiveness ratios (ICERs) were
calculated as the differences of average lifetime cost di-
vided by the difference of average life expectancy. Opti-
mization was approximated by calculating ICERs for
stepwise modified prevention strategies, including screen-
ing and complication treatments for variable population
risk characteristics. RESULTS: Compared to the progno-
sis of overall life expectancy and cost consequences the
more refined stepwise approach generates a series of re-
sults for all combinations of intervention strategy and
population subgroup. At certain risk levels the ICER
based treatment recommendation may change if sub-
group prognosis is applied. But for all age groups of dia-
betes patients secondary prevention of complication is
the dominant variant. Medical outcomes and incremental
cost-effectiveness are improved by additional secondary
prevention measures except for patients with non-revers-
ible risks. The potential savings from improved preven-
tion amount to 10% of total expenditures for diabetes
care in Germany, i.e., DEM 3000 million. CONCLU-
SIONS: With the stepwise assessment of subgroup out-
comes a treatment optimization and optimal allocation of
diabetes management to patient subgroups is feasible. Us-
ing average data to calculate overall ICER for the total
diabetes population may ignore the best treatment strat-
egy in different population subgroups. Subgroup analysis
represents a helpful tool in the health economic evalua-
tion of diabetes treatment strategies when variable popu-
lation risk characteristics and baseline complications af-
fect the clinical and economic outcome.
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OBJECTIVE: Evaluate the impact of a comprehensive di-
abetes disease management (DM) program on health care
costs, quality of life and patient satisfaction. METHODS:
Diabetes patients targeted by pharmacy claims were in-
vited to enroll in a voluntary payor-sponsored DM pro-
gram (n  2,178). Eligible non-enrollees were used for
the control group (n  6,396). Medical and pharmacy
claims were combined to determine health care costs.
Quality of life and patient satisfaction were also assessed,
via patient interview. The analysis timeframe encom-
passed two years prior and one year following program
initiation. RESULTS: Enrollees had higher direct health
care costs than non-enrollees. We were able to predict ac-
curately the medical spend in our control group in ab-
sence of intervention with standard time series analysis
within 4%. Following DM intervention, enrollees’ health
care spend was lower than their baseline spend and lower
than their projected spend ($116, $1,056). Con-
versely, health care spend increased in the non-enrollee
group from baseline ($714) (Table 1). Additionally, en-
rollee quality of life measures improved from baseline
and patient satisfaction with the DM program was high.
CONCLUSIONS: A comprehensive diabetes DM pro-
gram can lower health care cost and improve patient re-
ported quality of life while demonstrating consistently
high patient satisfaction.
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OBJECTIVES: Patient preferences for alternative treat-
ments may be affected by health status and experience
with the treatment. Randomized Clinical Trials (RCTs)
offer a unique opportunity to collect preference data
while controlling for patient experience. METHODS: Pa-
tients with Type II diabetes in a large US RCT answered a
series of stated preference (conjoint format) questions re-
garding attributes of alternative insulin therapies. All pa-
tients are insulin-naïve and take insulin as part of the
trial. Preference data is collected before the patient begins
insulin, after 3 months, and after 6 months of insulin
therapy. Insulin attributes include the frequency of insu-
lin injections, method of injection (syringe or pen), glu-
cose control and frequency of hypoglycemia. Personal
health data such as glucose control are collected at each
administration of the stated preference survey. RE-
SULTS: Preferences are analyzed in an ordered probit
panel model that controls for individual health status. In-
sulin administration attributes have the largest impor-
tance scores. The importance score of the insulin injec-
tion frequency attribute decreases during the later
observation points. While few patients experience night-
time hypoglycemia, this attribute is significant and has a
larger importance score than glucose control. CONCLU-
SIONS: Patient experience significantly affects patient
preferences and the derived pharmacoeconomic measures
and should be controlled in preference experiments. Re-
sults suggest that some insulin-naïve patients are more
averse to insulin injections before they begin insulin ther-
apy. Results also suggest that increased experience with
diabetes control measures during the trial affects treat-
ment preferences.
